<DOC>
	<DOCNO>NCT00230373</DOCNO>
	<brief_summary>Localized scleroderma morphea fibrotic disease , imiquimod induces cytokine inhibit fibrotic activity . We propose topical imiquimod 5 % cream efficacious safe treat plaque-type morphea . Twenty adult enrol pilot study . A screening baseline clinic visit require patient enrol study . Each visit involve complete medical history , skin examination , digital picture , histologic examination patient consent ultrasonographic score . One morphea plaque treat topical imiquimod 5 % cream , another morphea lesion vehicle cream . Patients ask side effect ( local systemic ) . Patients follow clinic 3 , 6 9 month therapy , 3 month follow end treatment period ( month 12 ) .</brief_summary>
	<brief_title>Imiquimod 5 % Cream Plaque-type Morphea : A Pilot , Prospective Open-label Study</brief_title>
	<detailed_description />
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Adults child &gt; 6 year plaquetype morphea Subject participate previous study involve imiquimod three month In investigator 's judgement , imiquimod treatment may benefit patient conventional treatment Subject provide informed write consent Female subject childbearing potential pregnancy urine test negative prior treatment Sexually active subject agree practice effective birth control throughout duration study Patients nonmorphea skin disorder region interest Subjects previously undergoing morphea therapy within four week study Subjects know hypersensitivity imiquimod component cream preparation Subjects pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Localized scleroderma</keyword>
</DOC>